A medicinal patent right in the United States. The assets offer the company access to several new technologies including the new generation immune modulator XR.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Rafarma Pharmaceuticals (Laskavy Patent)‘s full profile, request access.
Request a free trial